Jaka jest cena za Marizyme, Inc. (MRZM)

Cena za Marizyme, Inc. (MRZM) wynosi $0.0003

Jaka jest kapitalizacja rynkowa dla Marizyme, Inc. (MRZM)

Kapitalizacja rynkowa dla Marizyme, Inc. (MRZM) wynosi $39.54K

Marizyme, Inc. (MRZM) Wskaźnik C/Z

Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.

Rok	Wskaźnik P/E	Zmień
Za mało danych dla podanych dat.

Rok

Wskaźnik P/E

Zmień

Za mało danych dla podanych dat.

Firma	Wskaźnik P/E	Różnica wskaźnika P/E	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	28.05	-	US
Argenx SE ARGX.US	31.14	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	19.30	-	BE

Firma

Wskaźnik P/E

Różnica wskaźnika P/E

Kraj